Pfizer Inc. Chief Executive Ian Read said the company could see as many as 15 approvals over the next five years with sales potential of $1 billion a year or more, and half of those by 2020. "Pfizer Waiting for Cues on Tax Reform to Pursue Deals -- Update," published Aug. 1, 2017, at 1:19 p.m. EDT, incorrectly stated the company could see as many as 15 approvals by 2020 with blockbuster sales potential in the ninth paragraph. (Aug. 2, 2017)

(END) Dow Jones Newswires

August 02, 2017 11:06 ET (15:06 GMT)

Copyright (c) 2017 Dow Jones & Company, Inc.
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more AstraZeneca Charts.
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more AstraZeneca Charts.